TMCnet News
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Kythera Biopharmaceuticals Inc. Concerning Its Proposed Sale to Allergan plc - KYTHThe Rosen Law Firm, a global investor rights law firm, announces that it is investigating the Board of Directors of Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Kythera to maximize shareholder value before agreeing to be acquired by Allergan plc (NYSE:AGN (News - Alert)). If you would like to join the action, go to the firm's website at http://rosenlegal.com/cases-648.html or contact Phillip Kim or Kevin Chan toll-free at 866-767-3653 or via e-mail at [email protected] or [email protected]. There is no cost or obligation to you. Under the terms of the proposed transaction, shareholders will receive $75.00 in cash and stock for each share of Kythera common stock they own. The proposed transaction is valued at approximately $2.1 billion. The investigation relates to whether the proposal is fair to the public shareholders of Kythera and whether Kythera's Board breached its fiduciary duties in connection with the proposed sale. If you currently own shares of Kythera and wish to obtain additional information, please visit the firm's website at http://rosenlegal.com/cases-648.html. You may also contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150622006446/en/ |
